 |
 |
|
|
RESÚMENES ENERO 2008 |
-Psychotic Disorders
& Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
5 – doble-ciego o
metanálisis; 4 – subanálisis o simple ciego; 3 –
revisión, abierto, básico; 2 – casos; 1 – opinión
GRATIS = Texto gratuito en algunos
países de la región iberoamericana (algunos artículos requieren ir a la tabla
de contenidos del número actual de la revista)
GRATIS 3! -
Inpatient to Outpatient Status: Clinical Considerations in the Transitional
Treatment of Schizophrenia
David C. Henderson,
CNS Spectr.
2007;12:12(Suppl 21):1-20
GRATIS 3 -
Complementary Therapies for Schizophrenia: Expanding the Clinician's Toolbox
Psych Times. September 09,
2007
GRATIS 3 - Is remission in schizophrenia
possible?
Hélio Elkis
Rev.
Psiq. Clín. 34, supl 2; 160-163, 2007
GRATIS 3 - Early
detection: is it possible to prevent schizophrenia?
LOUZA, Mário
Rodrigues
Rev. psiquiatr.
clín., 2007, vol.34 suppl.2, p.169-173
GRATIS 3 -
Cognitive deficits in schizophrenia: functional consequences and
therapeutic approaches
MONTEIRO, Luciana de Carvalho
and LOUZA, Mário Rodrigues
Rev.
psiquiatr. clín.,
2007, vol.34 suppl.2, p.179-183
GRATIS 3 - Weight
gain and metabolic disorders in schizophrenia
LEITAO-AZEVEDO,
Carmem Lucia, GUIMARAES, Lísia Rejane, LOBATO, Maria Inês et al.
Rev. psiquiatr. clín., 2007, vol.34 suppl.2, p.184-188
GRATIS 3 - Compliance in
schizophrenia
ROSA, Moacyr
Alexandre and ELKIS, Hélio
Rev. psiquiatr. clín., 2007, vol.34 suppl.2, p.189-192
GRATIS 3 - New
antipsychotics for the treatment of schizophrenia
ELKIS, Hélio and
LOUZA, Mário Rodrigues
Rev. psiquiatr. clín., 2007, vol.34 suppl.2, p.193-197
GRATIS 3 - Smoking and Schizophrenia
society for neuroscience
3 - Quetiapine Extended-Release
Versus Immediate-Release Formulation: A Positron
Emission Tomography Study
David C. Mamo, Hiroyuki Uchida, Irina Vitcu,
Penny Barsoum, Alain Gendron,
Jeffrey Goldstein, and Shitij Kapur
J Clin Psychiatry January 3,
2008: e1-e6 (pii: ej07m03467
3! - Pharmacogenetics and
treatment response in schizophrenia
V. Moulier,
D. Januel
L’Encéphale Vol 33 - N° 6 - Décembre 2007 : 954 - 964
3< - Long-acting injectable risperidone: Naturalistic study in three hospitals in
C. Raignoux, T. Dusouchet,
P. Bret, E. Queuille, M.-L. Biscay,
J. Caron, M.C. Bret
L’Encéphale Vol 33 - N° 6 - Décembre 2007 ; 973 - 981
Psychiatr News January 4, 2008; Volume 43, Number 1, page 4
gratis 3 - FDA Evaluating New Drugs for Schizophrenia Treatment
Jun Yan
3! -
Infections in the CNS During Childhood and the Risk of
Subsequent Psychotic Illness: A Cohort Study of More Than One Million Swedish
Subjects
Christina Dalman, Peter Allebeck,
David Gunnell, Glyn Harrison, Krister
Kristensson, Glyn Lewis, Sofia Lofving,
Finn Rasmussen, Susanne Wicks, Håkan Karlsson
Am J
Psychiatry 2008; 165:59-65
5< -
Galantamine for the Treatment of Cognitive
Impairments in People With Schizophrenia
Robert W. Buchanan, Robert R. Conley, Dwight Dickinson, M. Patricia Ball,
Stephanie Feldman, James M. Gold, and Robert P. McMahon
Am J
Psychiatry 2008; 165:82-89
3! -
Selected Infectious Agents and Risk of Schizophrenia Among
David W. Niebuhr, Amy M. Millikan, David N. Cowan, Robert Yolken, Yuanzhang Li, and Natalya
S. Weber
Am J
Psychiatry 2008; 165:99-106
3! - Prediction of Psychosis in
Youth at High Clinical Risk. A Multisite Longitudinal Study in
Tyrone D. Cannon, Kristin Cadenhead, Barbara Cornblatt,
Scott W. Woods, Jean Addington, Elaine Walker, Larry
J. Seidman, Diana Perkins, Ming Tsuang,
Thomas McGlashan, Robert Heinssen
Arch Gen Psychiatry. 2008;65(1):28-37
GRATIS 4! - Evaluating dose response from flexible dose
clinical trials
Ilya Lipkovich, David H Adams, Craig Mallinckrodt, Doug Faries,
David A Baron and John P Houston
5 - Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight
Gain. A Randomized Controlled Trial
Ren-Rong Wu, Jing-Ping Zhao, Hua Jin, Ping Shao, Mao-Sheng Fang, Xiao-Feng Guo, Yi-Qun He, Yi-Jun Liu,
Jin-Dong Chen, Le-Hua Li
3< -
Add-on mirtazapine enhances effects on cognition in
schizophrenic patients under stabilized treatment with clozapine
Delle Chiaie, Roberto; Salviati,
Massimo; Fiorentini, Samantha; Biondi,
Massimo
Experimental and
Clinical Psychopharmacology. 2007 Dec Vol 15(6)
563-568
3< - Aripiprazole: Effectiveness and safety under naturalistic
conditions
Di Lorenzo, Rosaria; Amoretti, Alessandra; Forghieri,
Matilde; Fiorini, Fiorenza; Genedani, Susanna; Rigatelli, Marco
Experimental and
Clinical Psychopharmacology. 2007 Dec Vol 15(6)
569-575
3 -
Comparing the Use and Discontinuation of Antipsychotics in Clinical Practice:
An Observational Study
Mark Taylor, Polash
Shajahan, and Stephen M. Lawrie
J Clin Psychiatry January 9, 2008: e1-e6; pii:
ej07m03095
3 -
Vardenafil in the Treatment of Erectile Dysfunction
in Outpatients With Chronic Schizophrenia: A
Flexible-Dose, Open-Label Study
Charalampos I. Mitsonis,
Panagiotis A. Mitropoulos, Nikolaos
P. Dimopoulos, Evangelia G.
Kararizou, Vasiliki V. Psarra, Fivos E. Tsakiris, and Maria-Nefeli E. Katsanou
J Clin Psychiatry January 9, 2008: e1-e7; pii:
ej07m03243
3 -
Statins are effective in treating dyslipidemia
among psychiatric patients using second-generation antipsychotic agents
Kari Ojala, Eila
Repo-Tiihonen, Jari Tiihonen, Leo Niskanen
Journal of Psychopharmacology, Vol. 22, No. 1, 33-38
(2008)
3 -
Risk of stroke with typical and atypical anti-psychotics: a retrospective
cohort study including unexposed subjects
Emilio Sacchetti, Gianluca Trifirò, Achille
Caputi, Cesare Turrina, Edoardo Spina, Claudio Cricelli, Ovidio Brignoli,
Emiliano Sessa, Giampiero Mazzaglia
Journal of
Psychopharmacology, Vol. 22, No. 1, 39-46 (2008)
3! -
Cholinergic hypothesis in psychosis following traumatic brain injury and
cholinergic hypothesis in schizophrenia: a link?
M. Bennouna,
V.B. Greene, L. Defranoux
L’Encephale. Vol 33 - N° 4-C1 -
Septembre 2007; p. 616 - 620
3 -
Treatment of tobacco use in smokers with schizophrenia
A. Dervaux, X. Laqueille
L’Encephale. Vol 33 - N° 4-C1 - Septembre 2007 ; p.
629 - 632
3 - Accuracy of body image
perception and preferred weight
loss strategies in schizophrenia: a controlled pilot
study
C. Loh, J. M. Meyer, S. G. Leckband
Acta Psychiatrica
Scandinavica 2008; 117 (2), 127–132
3 - Illicit drug
use in patients with psychotic
disorders compared with that in the general population: a cross-sectional
study
P. A. Ringen, I. Melle, A. B. Birkenæs,
J. A. Engh, A. Færden, H. Jónsdóttir, R. Nesvåg, A. Vaskinn, S. Friis, F. Larsen, S. Opjordsmoen, K. Sundet, O. A. Andreassen
Acta Psychiatrica
Scandinavica 2008; 117 (2), 133–138
3 - Compromised myelin integrity
during psychosis with repair during remission in drug-responding schizophrenia
David L. Garver,
Jennifer A. Holcomb and James D. Christensen
The
International Journal of Neuropsychopharmacology
(2008), 11:49-61
3! - Nicotine and clozapine effects on attentional
performance impaired by the NMDA antagonist dizocilpine
in female rats
Amir H. Rezvani,
Ehsan Kholdebarin,
Elizabeth Dawson and Edward D. Levin
The
International Journal of Neuropsychopharmacology
(2008), 11:63-70
3! - Sex, Race, and Smoking Impact
Olanzapine Exposure
Kristin L. Bigos, Bruce G. Pollock, Kim C. Coley, Del D. Miller,
Stephen R. Marder, Manickam
Aravagiri, Margaret A. Kirshner,
Lon S. Schneider, and Robert R. Bies
3 -
Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of
psychosis, and brain activity in rats
R.E. Nordquist, C. Risterucci,
J.L. Moreau, M. von Kienlin,
B. Künnecke, M. Maco, C. Freichel,
C. Riemer and W. Spooren
Neuropharmacology. Volume 54, Issue 2,
February 2008, Pages 405-416
3 -
Lack of association
between the −759C/T polymorphism of the 5-HT2C receptor gene
and olanzapine-induced weight gain among Korean
schizophrenic patients
M. Park, J.-H. Cho, S.-G. Kang, J.-E. Choi, S.-H.
Lee, L. Kim, H.-J. Lee
Journal of Clinical
Pharmacy and Therapeutics 2008; 33 (1), 55–60
5 -
Does schizoaffective disorder really exist? A systematic review of the studies
that compared schizoaffective disorder with schizophrenia or mood disorders
Elie Cheniaux, J. Landeira-Fernandez,
Leonardo Lessa Telles, José
Luiz M. Lessa, Allan Dias,
Teresa Duncan and Marcio Versiani
Journal of Affective
Disorders. Volume 106, Issue 3, March 2008, Pages 209-217
3 - Comparison
of the Effects of Olanzapine and Risperidone
Versus Placebo on Ghrelin
Plasma Levels
Roerig, James L; Steffen, Kristine J; Mitchell, James E;
Crosby, Ross D; Gosnell, Blake A
Journal of Clinical
Psychopharmacology. 28(1):21-26,
February 2008
3 - Predictors
of Antipsychotic-Induced Weight Gain in First-Episode Psychosis: Conclusions From a Randomized, Double-Blind, Controlled Prospective
Study of Olanzapine, Risperidone,
and Haloperidol
Saddichha, Sahoo; Ameen, Shahul; Akhtar, Sayeed
Journal of Clinical
Psychopharmacology. 28(1):27-31,
February 2008
5< - A
Pilot Study of Adjunctive Atomoxetine Treatment to
Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia
Friedman, Joseph I; Carpenter, David; Lu, Jing;
Fan, Jin; Tang, Cheuk Y; White, Leonard; Parrella, Michael; Bowler, Stephanie; Elbaz,
Zeinab; Flanagan, Lauren; Harvey, Philip D
Journal of Clinical
Psychopharmacology. 28(1):59-63, February
2008
3! -
RGS4 Polymorphisms Predict Clinical Manifestations and Responses to Risperidone Treatment in Patients With
Schizophrenia
Lane, Hsien-Yuan; Liu,
Yi-Ching; Huang, Chieh-Liang;
Chang, Yue-Cune; Wu, Po-Lun;
Huang, Chiung-Hsien; Tsai, Guochuan
E
Journal of Clinical
Psychopharmacology. 28(1):64-68,
February 2008
3< -
Reduction in Neuroleptic-Induced Movement Disorders
After a Switch to Quetiapine in Patients With Schizophrenia
Cortese, Leonardo; Caligiuri,
Michael P; Williams, Richard; Schieldrop, Peter; Manchanda, Rahul; Malla, Ashok; Harricharan, Raj
Journal of Clinical
Psychopharmacology. 28(1):69-73,
February 2008
3 -
Time to Discontinuation and Self-Discontinuation of Olanzapine
and Risperidone in Patients With
Schizophrenia in a Naturalistic Outpatient Setting
Kilzieh, Nael; Todd-Stenberg,
Jeffrey A; Kennedy, Annette; Wood, Amanda E; Tapp,
Andre M
Journal of Clinical Psychopharmacology.
28(1):74-77, February 2008
4 - Sex, Race, and Smoking Impact
Olanzapine Exposure
Kristin L. Bigos, Bruce G. Pollock, Kim C. Coley, Del D. Miller,
Stephen R. Marder, Manickam
Aravagiri, Margaret A. Kirshner,
Lon S. Schneider, and Robert R. Bies
5! -
A Randomized, Double-Blind Comparison of Clozapine
and High-Dose Olanzapine in Treatment-Resistant
Patients With Schizophrenia
Herbert Y. Meltzer, William V. Bobo, Ajanta Roy, Karu Jayathilake, Yuejin Chen, Aygun Ertugrul, A. Elif Anil Yagcioglu, and Joyce G.
Small
J Clin Psychiatry January 23, 2008: e1-e12; pii:
ej06m02381
GRATIS 3 -
The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ
Qian Bian, Takahiro Kato, Akira Monji,
Sadayuki Hashioka, Yoshito Mizoguchi, Hideki Horikawa and Shigenobu Kanba
GRATIS 3! -
Possible association between the − 2548A/G polymorphism of the leptin gene and olanzapine-induced
weight gain
Seung-Gul Kang, Heon-Jeong Lee, Young-Min Park, Jung-Eun
Choi, Changsu Han, Yong-Ku
Kim, Seung-Hyun Kim, Min-Soo
Lee, Sook-Haeng Joe, In-Kwa
Jung and Leen Kim
3 -
Antipsychotic prescription patterns in outpatient settings: 24-month results
from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO)
study
Istvan Bitter, Tamas Treuer, Yulia Dyachkova, Ferenc Martenyi, Margaret McBridec
and Gabor S. UngvariEuropean Neuropsychopharmacology. Volume 18, Issue 3, March 2008, Pages
170-180
J
Clin Psychiatry 2008;69:81-86
J
Clin Psychiatry 2008;69:106-113